Seoul St. Mary's Hospital Selected as Lead Institution for 'Bio Core Facility'

101 Billion Won Support Over 7 Years... Promoting Growth of Emerging Bioventure

Seoul St. Mary's Hospital.

[Asia Economy Reporter Lee Gwan-joo] Catholic University Seoul St. Mary's Hospital announced on the 22nd that it has been selected as the lead institution for the "Bio Core Facility" construction project supported by the Ministry of Science and ICT and the National Research Foundation of Korea.

Seoul St. Mary's Hospital will receive a total of 10.1 billion KRW in support over seven years until 2028. Aiming to discover promising companies in cell and immune therapy, the hospital plans to provide ▲ support for clinical trials and regulatory approval of cell and immune therapeutics ▲ genome analysis and cell production support systems ▲ support for standardization of manufacturing technologies and development of standard operating procedures ▲ operation of technology development, technology investment, technology commercialization, regulatory law, and patent mentoring teams ▲ research staff training programs for resident companies ▲ investment maintenance for startup growth ▲ office and laboratory spaces.

Hospital Director Yoon Seung-gyu said, "Based on the abundant infrastructure of the Biomedical Industry Research Institute, we will spare no effort to support venture and startup companies scheduled to move in so that they can grow efficiently and devote themselves to developing core technologies and therapeutics to overcome diseases through 'patient-customized cell immune therapy development.'"

Meanwhile, the "Bio Core Facility" construction project is a national initiative that promotes the efficient growth of startup bio-venture companies with innovative ideas and core technologies by providing not only technology, equipment, and facilities but also consulting, education, and mentoring.

This content was produced with the assistance of AI translation services.